SCHEMBL4227329

SCHEMBL4227329

CCOC(=O)C=Cc1ccc(NC2CCN(C(=O)OC(C)(C)C)CC2)nc1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NOS2 P35228 5/20 0.52
NOS1 P29475 4/20 0.50
NOS3 P29474 2/20 0.50
SYK P43405 1/20 0.47
ALDH1A1 P00352 2/20 0.47
MAP4K4 O95819 1/20 0.46
MAPT P10636 2/20 0.46
NPC1 O15118 1/20 0.46
MAPK1 P28482 1/20 0.46
HTT P42858 1/20 0.46
RAB9A P51151 1/20 0.46
L3MBTL1 Q9Y468 1/20 0.46
LMNA P02545 1/20 0.45
THRB P10828 1/20 0.45
CCNT1 O60563 1/20 0.45
DDB1 Q16531 1/20 0.45
CRBN Q96SW2 1/20 0.45
JAK1 P23458 1/20 0.44
POLB P06746 1/20 0.44
HSD17B10 Q99714 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4217550 1.00 NOS2 (0.52) NOS2NOS1NOS3SYKALDH1A1
SCHEMBL4233336 0.87 NOS2 (0.51) NOS2NOS1NOS3ALDH1A1MAP4K4
SCHEMBL4233333 0.87 NOS2 (0.51) NOS2NOS1NOS3ALDH1A1MAP4K4
SCHEMBL4218960 0.83 NOS2 (0.47) NOS2NOS1NOS3MAP4K4MAPT
SCHEMBL4218968 0.83 NOS2 (0.47) NOS2NOS1NOS3MAP4K4MAPT
SCHEMBL4222903 0.82 USP30 (0.51) SYKALDH1A1MAPTNPC1MAPK1
SCHEMBL4222915 0.82 USP30 (0.51) SYKALDH1A1MAPTNPC1MAPK1
SCHEMBL10317400 0.82 SMN1; SMN2 (0.54) ALDH1A1MAP4K4HTTRAB9ALMNA
SCHEMBL10317402 0.82 SMN1; SMN2 (0.54) ALDH1A1MAP4K4HTTRAB9ALMNA
SCHEMBL16976334 0.80 SYK (0.58) NOS2NOS1NOS3SYKALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7557127-B2 HDAC inhibitor ASTELLAS PHARMA INC. (JP) 2009-07-07 US disclosed
US-20090054464-A1 HDAC INHIBITOR ASTELLAS PHARMA INC. (JP) 2009-02-26 US disclosed
US-7465731-B2 HDAC inhibitor ASTELLAS PHARMA INC. (JP) 2008-12-16 US disclosed
US-20060052599-A1 HDAC inhibitor ASTELLAS PHARMA INC. (JP) 2006-03-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060052599-A1 HDAC inhibitor HDAC1, HDAC2, HDAC11 NOS2 3761/4885NOS1 3471/4885NOS3 4122/4885
US-20090054464-A1 HDAC INHIBITOR HDAC1, HDAC2, HDAC8 NOS2 3815/4885NOS1 3647/4885NOS3 4184/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.